In conclusion, our study shows that after one cycle of RTX therapy the improvement in clinical and laboratory indices in RA patients was associated with the downregulation of the non-tissue specific regulatory genes MTOR, ULK1, p21, caspase 3, cytokines TNFα and IL-1β, and protease cathepsin K to healthy control levels. This evidence concerns the gene MTOR and rheumatoid arthritis.